Jubilant Pharmova
Market cap ₹14,787 Cr
- P/E
- 56.38
- Day range
- ₹931.00 – ₹953.90
- 52-week range
- ₹786.05 – ₹1,142.00
- Volume
- 1.35 L
- Open
- ₹949.95
- Prev close
- ₹954.50
Latest results · Q2 FY27(consolidated)Revenue ₹2,370 Cr+20.5%Profit ₹31 Cr-74.1%Margin 1.3%YoY vs the same quarter last year
No red flags in exchange filings: no rising pledge, promoter selling, surveillance or critical filing on record.
JUBLPHARMA in NSE indices and F&O
Research profile
Composite 46 / 100Factor percentiles
Derived metrics
- Earn. yield
- 1.8%
- Graham no.
- ₹426.71
- vs Graham
- -54.3%
- ROE ÷ P/B
- 2.8%
- 12-1 mom.
- -17.6%
- Return / vol
- -0.62
- Magic Formula
- #553
- Piotroski
- 1/6
- FCF yield
- -1.5%
Appears in 6 scans
Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.
Peer comparison
All 68 in Pharma| Company | M-cap | P/E | P/B | ROE | ROCE | OPM | D/E | Sales YoY |
|---|---|---|---|---|---|---|---|---|
| Sun PharmaSUNPHARMA | ₹4.49 L Cr | 40.95 | 5.03 | 14.8% | 21.0% | 29.0% | 0.04 | +11.9% |
| Divi's LaboratoriesDIVISLAB | ₹2.93 L Cr | 87.19 | 16.88 | 16.2% | 22.0% | 43.0% | 0.00 | +35.4% |
| Torrent PharmaTORNTPHARM | ₹1.75 L Cr | 77.88 | 9.67 | 26.8% | 15.0% | 33.0% | 0.77 | +50.8% |
| Apollo HospitalsAPOLLOHOSP | ₹1.27 L Cr | 56.40 | 11.55 | 22.6% | 17.0% | 16.0% | 0.77 | +23.0% |
| Laurus LabsLAURUSLABS | ₹1.25 L Cr | 93.72 | 19.82 | 18.2% | 18.0% | 34.0% | 0.43 | +33.5% |
| Zydus LifesciencesZYDUSLIFE | ₹1.20 L Cr | 28.72 | 4.32 | 20.1% | 21.0% | 24.0% | 0.50 | +29.2% |
| Dr. Reddy's LabsDRREDDY | ₹1.17 L Cr | 41.63 | 2.97 | 11.6% | 13.0% | 20.0% | 0.19 | -1.5% |
| Jubilant PharmovaJUBLPHARMA | ₹14,787 Cr | 56.38 | 2.14 | 6.0% | 9.0% | 10.0% | 0.60 | +20.5% |
| Sector median | ₹24,603 Cr | 43.68 | 5.46 | 15.1% | 17.0% | 24.0% | 0.17 | +22.7% |
Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.
Latest news
Updated 11h agoHeadlines about Jubilant Pharmova from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.
Key metrics
- P/E (TTM)
- 51.8
- Price / Book
- 2.08
- ROE (FY26)
- 6.0%
- ROCE (latest year)
- 9%
- Dividend yield
- 0.52%
Moving averages (NSE)
- 20-day
- ₹948.55
- Price below
- 50-day
- ₹978.21
- Price below
- 200-day
- ₹941.98
- Price below
Charts & trends
From company filings. Amounts in ₹ crore.
Revenue, profit & margin - quarterly
₹ crore; a loss shows red. Operating margin below, same periods.
- Revenue
- Net profit
Operating margin
Who owns the company
% of equity by quarter, latest Sept 2026
- Promoter
- Public
- FII
- DII
- Others
Cash flows
Where cash came from and went, by fiscal year (₹ crore)
- Operating
- Investing
- Financing
- Free cash flow
Return on equity
Net profit over shareholders' equity, by fiscal year
Equity vs debt
Shareholders' equity against borrowings (₹ crore); the ratio below, same years.
- Equity
- Debt
Debt to equity
Dividends per share
₹ by fiscal year of the ex-date; the latest year runs to date.
Financial statements
| Line item | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,677 | 1,759 | 1,732 | 1,752 | 1,822 | 1,929 | 1,901 | 1,966 | 2,122 | 2,290 | 2,229 | 2,370 |
| Expenses | 1,459 | 1,487 | 1,480 | 1,463 | 1,535 | 1,584 | 1,611 | 1,625 | 1,833 | 1,951 | 1,981 | 2,130 |
| Operating Profit | 218 | 271 | 252 | 289 | 287 | 345 | 290 | 341 | 289 | 339 | 248 | 240 |
| OPM % | 13% | 15% | 15% | 17% | 16% | 18% | 15% | 17% | 14% | 15% | 11% | 10% |
| Other Income | 49 | -151 | 410 | 8 | -10 | 9 | 12 | 4 | -19 | 10 | 20 | 14 |
| Interest | 71 | 73 | 71 | 61 | 56 | 53 | 49 | 50 | 56 | 56 | 54 | 58 |
| Depreciation | 95 | 101 | 91 | 91 | 91 | 95 | 98 | 105 | 121 | 117 | 127 | 135 |
| Profit before tax | 101 | -54 | 500 | 144 | 130 | 206 | 154 | 190 | 93 | 176 | 86 | 62 |
| Tax % | 34% | 15% | 4% | 29% | 23% | 27% | 34% | 37% | 40% | 32% | 35% | 50% |
| Net Profit | 66 | -62 | 482 | 102 | 101 | 151 | 102 | 120 | 56 | 119 | 56 | 31 |
| EPS in Rs | ₹4.19 | ₹-3.68 | ₹30.26 | ₹6.45 | ₹6.33 | ₹9.64 | ₹6.46 | ₹7.55 | ₹3.51 | ₹7.50 | ₹3.55 | ₹1.96 |
From company filings, updated 17 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.
Working-capital cycle
-2 days since Mar 2021
-98 days since Mar 2021
+46 days since Mar 2021
-147 days since Mar 2021
-61 days since Mar 2021
Strengths, risks & growth
Jubilant Pharmova Ltd is an integrated global pharmaceuticals company having three business segments i.e. pharmaceuticals, contract research and development services and proprietary novel drugs. [1]
Strengths
- Company has been maintaining a healthy dividend payout of 43.9%
- Company's working capital requirements have reduced from 28.6 days to 13.4 days
Risks
- The company has delivered a poor sales growth of 6.31% over past five years.
- Company has a low return on equity of 4.91% over last 3 years.
- Company might be capitalizing the interest cost
Compounded Sales Growth
- 10 Years
- +4%
- 5 Years
- +6%
- 3 Years
- +10%
- TTM
- +18%
Compounded Profit Growth
- 10 Years
- +1%
- 5 Years
- -13%
- 3 Years
- +47%
- TTM
- -41%
Stock Price CAGR
- 10 Years
- +6%
- 5 Years
- +9%
- 3 Years
- +31%
- 1 Year
- -17%
Return on Equity
- 10 Years
- +9%
- 5 Years
- +3%
- 3 Years
- +5%
- Last Year
- +7%
Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.
Shareholding pattern
| Holder | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 | Change |
|---|---|---|---|---|---|
| Promoter | 47.67% | 47.67% | 47.67% | 47.67% | 0.00 pp |
| FII | 15.96% | 15.90% | 15.87% | 15.37% | -0.50 pp |
| DII | 11.23% | 11.63% | 12.40% | 13.01% | +0.61 pp |
| Public | 24.57% | 24.25% | 23.50% | 23.38% | -0.12 pp |
| Others | 0.57% | 0.56% | 0.55% | 0.55% | 0.00 pp |
Filed with NSE for Sept 2026: promoters 47.68%, public 51.78%
Analysts & fund holdings
Who holds the shares, quarter by quarter
Mutual funds 9.47% (+0.43 pp)- Promoters47.9%
- Foreign institutions15.5%
- Mutual funds9.5%
- Insurance1.1%
- Other domestic institutions2.5%
- Retail10.7%
- Others12.8%
| Fund | % of company | % of fund | 3-month change |
|---|---|---|---|
| Bandhan Small Cap Fund | 3.62% | 1.56% | +0.37 pp |
| Kotak Multi Cap Fund | 1.11% | 0.57% | -0.03 pp |
| Bandhan Focused Fund | 0.81% | 5.92% | +0.56 pp |
| Abakkus Flexi Cap Fund | 0.37% | 0.70% | +0.69 pp |
| Aditya Birla SL Small Cap Fund | 0.30% | 0.79% | -0.01 pp |
Scorecard
- Performance
- Low
- Valuation
- High
- Growth
- Low
- Profitability
- High
- Entry point
- Good
- Red flags
- Low
Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.
Risk & trend
From 292 daily sessions to 18 Nov 2026.
Risk
- Volatility (1Y)
- 28.8%
- Downside volatility
- 27.5%
- Worst 5% of days
- 2.6%
- Average of that tail
- 3.8%
- Max drawdown (1Y)
- 31.6%
- Below its peak
- 21.0%
Against the market
- Beta vs Nifty 50
- 0.61
- Correlation
- 0.28
- Relative strength (3M)
- +3.8%
- ATR (14)
- 3.5%
Return
- Return 1M
- -0.5%
- Return 3M
- +7.7%
- Return 6M
- -7.5%
- Return 1Y
- -18.0%
- vs 200-day average
- -0.9%
Momentum
- RSI (14)
- 42.7
- MACD histogram
- 1.18
- Stochastic %K
- 17.8
- ADX (14)
- 15.6
- +DI / −DI
- 13.2 / 19.8
- Money flow index
- 38.6
Participation
- Delivery (20d avg)
- 44.7%
- vs its 60-day baseline
- -2.9 pts
- Volume vs 20-day
- +0.5σ
- Close vs day's VWAP
- -0.8%
- 52-week position
- 34 / 100
These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.
Financial quality
From consolidated statements to 31 Mar 2026.
Piotroski F-Score
1 of 6 tested
- Return on assets positive — passed
- Operating cash flow positive — not testableno cash flow statement for this period
- Return on assets improving — failed
- Cash flow exceeds profit — not testableneeds cash flow and profit against assets
- Debt to assets falling — failed
- Current ratio improving — failed
- No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
- Operating margin improving — failed
- Asset turnover improving — failed
- Free cash flow
- -₹222 Cr
- FCF yield
- -1.5%
- Cash conversion
- 3.09
- Accruals ratio
- -0.053
- Net debt
- ₹2,350 Cr
- Net debt / equity
- 0.33
- EV / sales
- 1.90
- Capex intensity
- 17.5%
- Revenue CAGR
- 18.7%
- Profit CAGR
- -21.2%
Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.
Insider trades
| Person | Type | Shares | Value | Disclosed |
|---|---|---|---|---|
Jubilant Employees Welfare Trust ESOP | Sell | 11,304 | ₹92.8 L | 12 Mar 2026 |
Disclosures filed with NSE under SEBI (Prohibition of Insider Trading) Regulations. Pledges and releases are not trades and are not counted above.
Corporate actions
- dividend₹5.00
Dividend - Rs 5 Per Share
24 Jul 2026ex-date - dividend₹5.00
Dividend - Rs 5 Per Share
25 Jul 2025ex-date - dividend₹5.00
Dividend - Rs 5 Per Share
2 Aug 2024ex-date - dividend₹5.00
Dividend - Rs 5 Per Share
10 Aug 2023ex-date - dividend₹5.00
Dividend - Rs 5 Per Share
11 Aug 2022ex-date - dividend₹5.00
Dividend - Rs 5 Per Share
5 Aug 2021ex-date - otherNot available — not reported in this filing
Demerger
4 Feb 2021ex-date - dividend₹5.00
Interim Dividend - Rs 5 Per Share
9 Mar 2020ex-date - dividend₹4.50
Annual General Meeting/Dividend - Rs 4.50 Per Share
12 Sept 2019ex-date - dividend₹3.00
Annual General Meeting/Dividend Rs 3 Per Share
12 Sept 2018ex-date - dividend₹3.00
Annual General Meeting/ Dividend - Rs 3/- Per Share
16 Aug 2017ex-date - dividend₹3.00
Annual General Meeting/ Dividend - Rs 3/- Per Share
18 Aug 2016ex-date - dividend₹3.00
Annual General Meeting/ Dividend - Rs 3/- Per Share
20 Aug 2015ex-date - dividend₹3.00
Annual General Meeting / Dividend - Rs 3/- Per Share
21 Aug 2014ex-date - dividend₹3.00
Annual General Meeting And Dividend Rs.3/- Per Share
14 Aug 2013ex-date - dividend₹3.00
Annual General Meeting/ Dividend Rs 3 Per Share
14 Aug 2012ex-date - dividend₹2.00
Annual General Meeting And Dividend Rs.2/- Per Share
10 Aug 2011ex-date - otherNot available — not reported in this filing
Scheme Of Demerger
25 Nov 2010ex-date - dividend₹2.00
Annual General Meeting And Dividend Rs.2/- Per Share
17 Sept 2010ex-date - dividend₹1.50
Dividend-Rs.1.50 Pr Share
29 Jun 2009ex-date
Company announcements
Investor Meet Outcome
Newspaper Publication
Press Release
Un-audited Financial Results for the Quarter and Half Year ended September 30, 2026
Outcome of Board Meeting
Press Release
Allotment
Allotment of NCD
Earning Webinar
Jubilant Pharmova Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2026 ,inter alia, to consider and approve Unaudited standalone and ....
Newspaper Publication
Newspaper Publication
Postal Ballot Notice
Credit Rating
Announcement under Regulation 30 - Credit Rating
Filed with BSE (scrip 530019); the last 45 days. Documents open at bseindia.com.
Documents
Annual reports
Earnings calls
- Nov 2026Recording
- Aug 2026Slides
- May 2026TranscriptSlides
- Feb 2026Slides
- Oct 2025Slides
- Jul 2025TranscriptSlides
Credit ratings
- Rating update · 21 Oct from fitch
- Rating update · 14 Oct from icra
- Rating update · 24 Feb from fitch
- Rating update · 5 May 2025 from fitch
- Rating update · 26 Dec 2022 from fitch
- Rating update · 26 May 2021 from fitch
Documents open at BSE or the rating agency that issued them.
Sourced from the company's NSE XBRL filing dated 14 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.
Jubilant Pharmova: common questions
Answered from the figures on this page.